Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases

…, T Semalulu, G Foster, S Surangiwala… - The Lancet …, 2021 - thelancet.com
Background The impact and consequences of the COVID-19 pandemic on people with
rheumatic disease are unclear. We developed the COVID-19 Global Rheumatology Alliance …

Regional variability in fecal microbiota transplantation practices: a survey of the Southern Ontario Fecal Microbiota Transplantation Movement

SS Hota, S Surangiwala, AS Paterson… - … Open Access Journal, 2018 - cmajopen.ca
Background: There is growing evidence that fecal microbiota transplantation (FMT) is an
effective treatment for recurrent Clostridium difficile infection, but little guidance exists for …

[PDF][PDF] Early impacts of the COVID-19 pandemic on children with pediatric rheumatic diseases

JS Hausmann, K Kennedy, S Surangiwala… - Eur J …, 2022 - eurjrheumatol.org
Objectives: The experiences of children with pediatric rheumatic diseases (PRD) during the
initial phase of the COVID-19 pandemic have not been well-documented. We sought to …

Is denosumab associated with an increased risk for infection in patients with low bone mineral density? A systematic review and meta‐analysis of randomized …

B Catton, S Surangiwala… - International Journal of …, 2021 - Wiley Online Library
Aim Denosumab increases bone mineral density through inhibition of the receptor activator
of nuclear factor κ‐Β ligand (RANKL). RANKL has known immunomodulatory effect. The …

Clinical Impact of Rapid Identification (ID) and Phenotypic Antimicrobial Susceptibility Testing (AST) by Accelerate Pheno™ System (AXDX) for Gram-negative (GNB) …

…, S Lee, V Koren, S Surangiwala… - Open Forum …, 2017 - academic.oup.com
Background Laboratory turn-around-times (TATs) for identification (ID) and antimicrobial
susceptibilities (AST) can delay prescription of adequate and/or optimal antimicrobial (ABX) …

Prospective Evaluation of Accelerate Pheno™ System (AXDX) Version 1.1 for Reducing Turn-Around-Time (TAT) in Identification/Antimicrobial Susceptibility Testing …

…, S Lee, V Koren, S Surangiwala… - Open Forum …, 2017 - academic.oup.com
Background The current standard technique for diagnosis of bloodstream infection (BSI) is
through the detection of micro-organisms using automated blood culture systems and …

[HTML][HTML] Student-led Evaluation of the McMaster University Tobacco and Smoke-Free Campus Policy

…, S Haalboom, S Surangiwala… - … in Health Promotion, 2018 - jps.library.utoronto.ca
Background: McMaster University is a Canadian post-secondary institution focused on
promoting health on campus in accordance with the 2015 Okanagan Charter. McMaster …

Retrospective Evaluation of Accelerate Pheno™ System (AXDX, Version 1.1) for Identification/Antimicrobial Susceptibility Testing (ID/AST) of Gram-Negative Bacilli …

…, S Lee, V Koren, S Surangiwala… - Open Forum …, 2017 - academic.oup.com
Background AXDX reports ID/AST in <7h from positive blood cultures. Prospective pre-FDA
clinical trials were conducted in areas where CPO bacteremia was rare. This study …

Su1191 ADULT-ONSET AUTOIMMUNE ENTEROPATHY: A SCOPING REVIEW

J Liu, MA Scaffidi, S Surangiwala, N Gimpaya… - …, 2020 - ncbi.nlm.nih.gov
Background: Enterocolitis is among the leading immune-related adverse events (irAEs)
associated with immune checkpoint inhibitors (ICIs)(anti-cytotoxic T-lymphocyte-associated …

[CITATION][C] Antimalarial drug shortages during the COVID-19 pandemic: results from the Global Rheumatology Alliance patient experience survey

E Sirotich, K Kennedy, S Surangiwala… - Arthritis & …, 2020 - pesquisa.bvsalud.org
Antimalarial Drug Shortages During the COVID-19 Pandemic: Results from the Global
Rheumatology Alliance Patient Experience Survey | Arthritis & Rheumatology; 72:4, 2020. | Web …